 Cantyns started around three years ago. We developed the idea for the blood test for bowel cancer ten years ago, but as the years went on and the grants kept coming in, such as Cancer Research Wales, we could see real potential for the test. We've applied a technic, a technology that's been around for some time called Raman spectroscopy, but we've utilised it in new ways, looking at a blood sample from a patient. And we're trying to make that test as accurate as possible by using the latest analytics. We get a reading out of that blood sample we compare to our AI technology and we report back our findings to the GP or a clinician, therefore reducing the anxiety for those patients in a timely fashion and giving them comfort that most don't have bowel cancer and for those that may do get prioritised as quickly as possible. I really hope that this will make a huge impact in the earlier detection of bowel cancer. The beauty of the technique that we've used is that it's a label-free technique that allows us in the future to be able to look at other challenges in other disease areas. We are absolutely delighted to be nominated for this St David award. I think it's just great recognition for how long we've come on the journey with CanSense and we're right on the cusp of making a massive difference to really improve bowel cancer outcomes for the people of Wales.